

Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), End User (Pediatric, Adult) - Global forecast to 2030

<https://marketpublishers.com/r/C745F3E6C527EN.html>

Date: October 2025

Pages: 305

Price: US\$ 4,950.00 (Single User License)

ID: C745F3E6C527EN

Abstracts

The global compounding pharmacy market is projected to reach USD 19.41 billion by 2030 from an estimated USD 14.72 billion in 2025, at a CAGR of 5.7% from 2025 to 2030. The market's growth has mainly been driven by the increasing trend toward personalized doses. However, capacity constraints in API, excipient supply, and CCI/testing are expected to limit the market.

The oral drugs held the highest share in the compounding pharmacy market by product type.

The compounding pharmacy market is segmented by product type into topical drugs, oral drugs, parenteral drugs, rectal drugs, nasal drugs, ophthalmic drugs, and other products. Among these, the oral drugs segment holds a key position in the global market, driven by the increasing need for personalized therapies tailored to individual patient requirements. This segment includes a wide variety of formulations such as capsules, tablets, lozenges, solutions, and suspensions, which are extensively used in hormone replacement therapy, pediatric and geriatric care, pain management, gastrointestinal treatments, and chronic disease management. Compounded oral medications enable pharmacists to customize dosage strengths, flavors, excipients, and release profiles, thereby improving patient compliance—especially among those who have difficulty swallowing standard tablets or who need precise dosing. The rising

prevalence of chronic conditions like cardiovascular diseases, diabetes, and endocrine disorders further fuels this segment's growth by creating demand for personalized oral treatments that maximize efficacy and reduce side effects. Technological innovations, including sustained-release systems, taste-masking techniques, and bioavailability-enhancing carriers, improve therapeutic performance and patient experience. Adherence to FDA regulations and USP standards ensures safety, sterility, and quality, building confidence among healthcare providers and patients. Along with the growing emphasis on personalized medicine and increased availability through hospitals, specialty clinics, and retail pharmacies, oral drugs continue to be a major driver of revenue growth. The segment's focus on convenience, customization, and effective therapy highlights its vital role in the overall development of the global compounding pharmacy market.

The pain management segment reported the highest share of the therapeutic application segment in 2024

The pain management segment holds the largest share in the pharmaceutical market by therapeutic application, driven by the global prevalence of acute and chronic pain conditions across musculoskeletal, neuropathic, and post-surgical patient groups. Increasing cases of arthritis, back pain, cancer-related pain, and migraines have boosted demand for effective pain relief therapies, including NSAIDs, opioids, topical analgesics, and combination treatments. The rising use of personalized pain management options, such as sustained-release formulations and targeted delivery systems, improves effectiveness while reducing systemic side effects, further increasing patient adherence and market growth. Technological advances, like transdermal patches and localized injectable therapies, have broadened treatment choices and made long-term pain management more convenient for patients. Favorable insurance coverage, greater awareness of pain as a key health issue, and the expanding elderly population support consistent growth in this segment. Leading pharmaceutical firms are enhancing their portfolios through research into new analgesics, biologics, and non-opioid alternatives, positioning themselves to capture larger market shares. As the need for safe, effective, and patient-focused pain management solutions continues to grow, this therapeutic segment is expected to stay dominant, reflecting sustained revenue increases and ongoing innovation in both developed and emerging markets.

North America accounted for the largest market share in the global Compounding pharmacy market from 2025 to 2030.

North America remains the leading region in the global compounding pharmacy market,

mainly due to the United States. The region's dominance is linked to its strong healthcare infrastructure, strict regulatory standards, and a large presence of both 503A and 503B compounding pharmacies. These pharmacies are essential in providing personalized medications, especially where commercially available drugs are insufficient. The US market offers a wide variety of compounded products, including oral, topical, and sterile preparations, to meet different therapeutic needs. Recent trends show a rising demand for specialized compounded medications, particularly in pain management, hormone replacement therapy, and pediatric care. Regulatory agencies like the FDA continue to monitor and ensure the safety and effectiveness of compounded drugs, building trust within the healthcare system. This combination of factors highlights North America's key role in advancing and improving access to compounding pharmacy services.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side-70% and Demand Side-30%

By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%

By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report:

Key players in the Compounding pharmacy market include Baxter (US), Empower Pharmacy (US), B. Braun (Germany), Fagron (Netherlands), QuVa Pharma (US), SCA Pharma (US), Nephron Pharmaceuticals (US), Leiters Health (US), Pharmaxo (UK), Icon Group (Australia), Roseway Labs (UK), ITH Pharma (UK), Pencol Compounding Pharmacy (Canada), Formula 8 (South Africa), and Aurora Compounding Pharmacy (Canada)

Research Coverage:

This research report categorizes the compounding pharmacy market by product (oral, topical, parenteral), compounding type (ingredient alteration, dosage alteration), therapeutic application (pain management, HRT), sterility (sterile), and end user (pediatric, adult). The scope of the report includes detailed information about the main factors affecting the growth of the Compounding pharmacy market, such as drivers,

restraints, challenges, and opportunities. It also features an in-depth analysis of key industry players, offering insights into their business overview, products, solutions, strategies, collaborations, partnerships, and agreements. The report covers recent developments like new approvals, launches, collaborations, acquisitions, and other updates related to the Compounding pharmacy market.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing them with the closest estimates of revenue figures for the entire Compounding pharmacy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop appropriate go-to-market strategies. This report will enable stakeholders to grasp the market's key indicators and offer information on the main market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (Persistent drug shortages in North America and Europe, full enforcement of USP standards, safety push for ready-to-administer and standardized doses, continued demand creating supply gap for GLP-1 drugs, and trend toward personalization of doses), restraints (Resolution of GLP-1 shortages reduces reliance on compounded alternatives, stricter FDA oversight and insanitary conditions enforcement, and limitations on bulk drug substances.), opportunities (Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic & chemo-adjuvants and Radiopharmaceutical compounding standardization), and challenges (Capacity bottlenecks in API, excipient supply, and CCI/testing, and limited quality-system maturity and gaps in stability/BUD evidence generation.) influencing the growth of the market.

Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the compounding pharmacy market

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the compounding pharmacy market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the Compounding pharmacy market.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.3 STUDY SCOPE

1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE

1.3.2 INCLUSIONS & EXCLUSIONS

1.3.3 YEARS CONSIDERED

1.3.4 CURRENCY CONSIDERED

1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

2.1.1 SECONDARY DATA

2.1.1.1 Objectives of secondary research

2.1.1.2 Key data from secondary sources

2.1.2 PRIMARY DATA

2.1.2.1 Breakdown of primaries (supply- and demand-side participants)

2.1.2.2 Key objectives of primary research

2.2 MARKET SIZE ESTIMATION

2.2.1 GLOBAL MARKET ESTIMATION

2.2.1.1 Company revenue analysis (bottom-up approach)

2.2.1.2 Revenue share analysis

2.2.1.3 MnM repository analysis

2.2.1.4 Primary interviews

2.2.2 INSIGHTS OF PRIMARY EXPERTS

2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)

2.3 MARKET GROWTH RATE PROJECTIONS

2.4 DATA TRIANGULATION

2.5 STUDY ASSUMPTIONS

2.6 RESEARCH LIMITATIONS

2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

3.1 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS

3.2.1 STARTUPS AND INNOVATIVE COMPANIES

3.2.2 ESTABLISHED MARKET LEADERS

4 PREMIUM INSIGHTS

4.1 COMPOUNDING PHARMACY MARKET OVERVIEW

4.2 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT AND COUNTRY (2025)

4.3 COMPOUNDING PHARMACY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4.4 COMPOUNDING PHARMACY MARKET: EMERGING VS. DEVELOPED MARKETS

4.5 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES

4.6 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS

4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE

4.8 REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Persistent drug shortages in North America and Europe

5.2.1.2 Enforcement of USP standards

5.2.1.3 Push for ready-to-administer (RTA) and standardized doses

5.2.1.4 Continued demand-supply gap for GLP-1 drugs

5.2.1.5 Trend towards personalization of doses

5.2.2 RESTRAINTS

5.2.2.1 Resolution of GLP-1 shortages and reduced reliance on compounded alternatives

5.2.2.2 Stricter FDA oversight and intensified enforcement of unsanitary conditions violations

5.2.2.3 Limitations on bulk drug substances

5.2.3 OPPORTUNITIES

5.2.3.1 Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic, and chemo-adjuvants

5.2.3.2 Radiopharmaceutical compounding standardization

5.2.4 CHALLENGES

5.2.4.1 Capacity bottlenecks in API, excipient supply, and critical compounding infrastructure testing

5.2.4.2 Limited quality-system maturity and gaps in stability/BUD evidence generation

5.3 PORTER'S FIVE FORCES ANALYSIS

5.3.1 THREAT OF NEW ENTRANTS

5.3.2 THREAT OF SUBSTITUTES

5.3.3 BARGAINING POWER OF SUPPLIERS

5.3.4 BARGAINING POWER OF BUYERS

5.3.5 INTENSITY OF COMPETITIVE RIVALRY

5.4 KEY STAKEHOLDERS & BUYING CRITERIA

5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.4.2 KEY BUYING CRITERIA

5.5 MACROECONOMICS INDICATORS

5.5.1 HEALTHCARE EXPENDITURE TRENDS

5.5.2 GLOBAL CANCER BURDEN

5.5.3 IMPACT OF PHARMA R&D

5.6 VALUE CHAIN ANALYSIS

5.7 ECOSYSTEM ANALYSIS

5.7.1 ROLE IN ECOSYSTEM

5.8 PRICING ANALYSIS

5.8.1 INDICATIVE PRICING ANALYSIS OF COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024

5.8.2 INDICATIVE PRICING ANALYSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024

5.9 KEY CONFERENCES & EVENTS, 2025–2026

5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.11 INVESTMENT & FUNDING SCENARIO

5.12 TECHNOLOGY ANALYSIS

5.12.1 KEY TECHNOLOGIES

5.12.1.1 Automated compounding devices

5.12.1.2 Sterile compounding equipment

5.12.2 COMPLEMENTARY TECHNOLOGIES

5.12.2.1 Quality control & testing systems

5.12.2.2 Pharmacy information management software (PIMS)

5.12.3 ADJACENT TECHNOLOGIES

5.12.3.1 3D printing of pharmaceuticals

5.12.3.2 Personalized medicine platforms

5.13 IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET

5.14 REGULATORY ANALYSIS

- 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
- 5.14.2 REGULATORY FRAMEWORK
- 5.15 IMPACT OF 2025 US TARIFF ON COMPOUNDING PHARMACY MARKET
 - 5.15.1 INTRODUCTION
 - 5.15.2 KEY TARIFF RATES
 - 5.15.3 PRICE IMPACT ANALYSIS
 - 5.15.4 IMPACT ON COUNTRY/REGION
 - 5.15.4.1 US
 - 5.15.4.2 Europe
 - 5.15.4.3 Asia Pacific
 - 5.15.4.4 Rest of the World
 - 5.15.5 IMPACT ON MANUFACTURING INDUSTRIES
- 5.16 UNMET NEEDS & WHITE SPACES

6 COMPOUNDING PHARMACY MARKET, BY PRODUCT

- 6.1 INTRODUCTION
- 6.2 ORAL DRUGS
 - 6.2.1 INCREASING DEMAND FOR PRECISE AND CUSTOMIZABLE ORAL FORMULATIONS IN UNMET PATIENT POPULATIONS TO DRIVE MARKET
- 6.3 TOPICAL DRUGS
 - 6.3.1 RISING DEMAND FOR PERSONALIZED TOPICAL TREATMENTS AND ADVANCED DELIVERY VEHICLES TO FUEL MARKET GROWTH
- 6.4 PARENTERAL DRUGS
 - 6.4.1 RISING DEMAND FOR STERILE INJECTABLE THERAPIES AND SUPPLY-CHAIN DISRUPTIONS TO BOOST MARKET GROWTH
- 6.5 OPHTHALMIC DRUGS
 - 6.5.1 RISING CASES OF EYE-RELATED DISORDERS TO ACCELERATE MARKET GROWTH
- 6.6 NASAL DRUGS
 - 6.6.1 ADVANCEMENTS IN NASAL DRUG DELIVERY SYSTEMS AND FAVORABLE REGULATORY POLICIES TO PROPEL MARKET GROWTH
- 6.7 RECTAL DRUGS
 - 6.7.1 PERSONALIZED FORMULATIONS AND REGULATORY SUPPORT TO DRIVE GROWTH IN RECTAL COMPOUNDING THERAPIES
- 6.8 OTHER PRODUCTS

7 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE

7.1 INTRODUCTION

7.2 PHARMACEUTICAL DOSAGE ALTERATION

7.2.1 TAILORED DOSAGE FORMS TO ENHANCE PATIENT ADHERENCE AND CUSTOMIZATION IN COMPOUNDED MEDICATIONS

7.3 PHARMACEUTICAL INGREDIENTS ALTERATION

7.3.1 INCREASED NEED FOR CUSTOMIZED PHARMACEUTICAL INGREDIENTS TO ENHANCE PATIENT-CENTRIC COMPOUNDING SOLUTIONS

7.4 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING

7.4.1 PERSISTENT GLOBAL DRUG SHORTAGES AND LIMITATIONS OF LARGE-SCALE PHARMACEUTICAL PRODUCTION TO PROPEL ADOPTION

8 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION

8.1 INTRODUCTION

8.2 PAIN MANAGEMENT

8.2.1 NEED FOR PERSONALIZED PAIN RELIEF SOLUTIONS FOR CHRONIC AILMENTS TO SUPPORT MARKET

8.3 HORMONE REPLACEMENT THERAPIES

8.3.1 POPULARITY OF PERSONALIZED HORMONE THERAPIES TO DRIVE STEADY GROWTH IN GLOBAL COMPOUNDING PHARMACY MARKET

8.4 DERMAL DISORDERS

8.4.1 CUSTOMIZED DERMATOLOGICAL SOLUTIONS TO PROPEL GLOBAL COMPOUNDING PHARMACY MARKET EXPANSION

8.5 NUTRITIONAL SUPPLEMENTS

8.5.1 PERSONALIZED NUTRACEUTICALS TO OFFER NICHE BUT BETTER GROWTH OPPORTUNITIES IN COMPOUNDING PHARMACIES

8.6 OTHER THERAPEUTIC APPLICATIONS

9 COMPOUNDING PHARMACY MARKET, BY STERILITY

9.1 INTRODUCTION

9.2 STERILE

9.2.1 RTU/RTA STERILE PREPARATIONS AND OPHTHALMIC PACKS TO DRIVE RAPID GROWTH IN COMPOUNDING PHARMACIES

9.3 NON-STERILE

9.3.1 503A/MAGISTRAL NON-STERILE PREPARATIONS TO DRIVE GLOBAL VOLUME AND VALUE LEADERSHIP IN COMPOUNDING PHARMACIES

10 COMPOUNDING PHARMACY MARKET, BY END USER

10.1 INTRODUCTION

10.2 ADULTS

10.2.1 RISING CHRONIC DISEASE BURDEN AND PERSONALIZED THERAPIES TO AUGMENT ADULT SEGMENT GROWTH

10.3 GERIATRIC PATIENTS

10.3.1 AGING DEMOGRAPHICS AND DOSE-FORM CUSTOMIZATION TO PROPEL GERIATRIC SEGMENT GROWTH

10.4 PEDIATRIC PATIENTS

10.4.1 CUSTOMIZED DOSAGE FORMS AND PEDIATRIC-SPECIFIC NEEDS TO DRIVE GROWTH

11 COMPOUNDING PHARMACY MARKET, BY REGION

11.1 INTRODUCTION

11.2 NORTH AMERICA

11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

11.2.2 US

11.2.2.1 US to dominate North American compounding pharmacy market during forecast period

11.2.3 CANADA

11.2.3.1 Personalized treatments, regulatory reinforcement, and supply-gap filling to fuel global compounding pharmacy growth

11.3 EUROPE

11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

11.3.2 GERMANY

11.3.2.1 Aging demographics, technological advancements, and supportive regulations to drive market

11.3.3 UK

11.3.3.1 Personalized treatments, chronic disease management, and regulatory support to support market growth

11.3.4 FRANCE

11.3.4.1 Focus on chronic disease management to fuel growth in French compounding pharmacy market

11.3.5 ITALY

11.3.5.1 Rising commercial drug development pipeline to spur market growth

11.3.6 SPAIN

11.3.6.1 Global regulatory advancements and rising R&D activities to drive market

11.3.7 REST OF EUROPE

11.4 ASIA PACIFIC

11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

11.4.2 CHINA

11.4.2.1 Low manufacturing cost and high demand for medicines to favor market growth

11.4.3 JAPAN

11.4.3.1 Increasing prevalence of chronic diseases and growing geriatric population to fuel demand for customized medications

11.4.4 INDIA

11.4.4.1 Increasing pharma R&D activities to support market growth

11.4.5 AUSTRALIA

11.4.5.1 Innovation in clinical practice and regulatory support to accelerate compounding pharmacy growth

11.4.6 SOUTH KOREA

11.4.6.1 Regulatory innovation and automation to fuel South Korean compounding pharmacy market growth

11.4.7 REST OF ASIA PACIFIC

11.5 LATIN AMERICA

11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

11.5.2 BRAZIL

11.5.2.1 Growing pharmacy & biologics manufacturing sectors and rising R&D spending to drive market

11.5.3 MEXICO

11.5.3.1 Regulatory improvements, high cancer rates, and robust pharmaceutical industry to boost market growth

11.5.4 REST OF LATIN AMERICA

11.6 MIDDLE EAST & AFRICA

11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11.6.2 GCC COUNTRIES

11.6.2.1 Rising demand for biologics and increasing prevalence of non-communicable diseases to propel market growth

11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN

COMPOUNDING PHARMACY MARKET, 2023-2025

12.3 REVENUE ANALYSIS, 2022-2024

12.4 MARKET SHARE ANALYSIS, 2024

12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

12.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024

12.5.5.1 Company footprint

12.5.5.2 Region footprint

12.5.5.3 Product footprint

12.5.5.4 Therapeutic application footprint

12.5.5.5 Sterility footprint

12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

12.6.1 PROGRESSIVE COMPANIES

12.6.2 RESPONSIVE COMPANIES

12.6.3 DYNAMIC COMPANIES

12.6.4 STARTING BLOCKS

12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

12.6.5.1 Detailed list of key startup/SMEs

12.6.5.2 Competitive benchmarking of key startups/SMEs

12.7 COMPANY VALUATION & FINANCIAL METRICS

12.7.1 FINANCIAL METRICS

12.7.2 COMPANY VALUATION

12.8 BRAND/PRODUCT COMPARISON

12.9 COMPETITIVE SCENARIO

12.9.1 PRODUCT LAUNCHES

12.9.2 DEALS

12.9.3 EXPANSIONS

13 COMPANY PROFILES

13.1 KEY PLAYERS

13.1.1 BAXTER

13.1.1.1 Business overview

13.1.1.2 Products offered

13.1.1.3 Recent developments

13.1.1.3.1 Product launches

- 13.1.1.4 MnM view
 - 13.1.1.4.1 Key strengths
 - 13.1.1.4.2 Strategic choices
 - 13.1.1.4.3 Weaknesses & competitive threats
- 13.1.2 EMPOWER PHARMACY
 - 13.1.2.1 Business overview
 - 13.1.2.2 Products offered
 - 13.1.2.3 Recent developments
 - 13.1.2.3.1 Expansions
 - 13.1.2.4 MnM view
 - 13.1.2.4.1 Key strengths
 - 13.1.2.4.2 Strategic choices
 - 13.1.2.4.3 Weaknesses & competitive threats
- 13.1.3 B. BRAUN SE
 - 13.1.3.1 Business overview
 - 13.1.3.2 Products offered
 - 13.1.3.3 Recent developments
 - 13.1.3.3.1 Product launches
 - 13.1.3.4 MnM view
 - 13.1.3.4.1 Key strengths
 - 13.1.3.4.2 Strategic choices
 - 13.1.3.4.3 Weaknesses & competitive threats
- 13.1.4 FAGRON
 - 13.1.4.1 Business overview
 - 13.1.4.2 Products offered
 - 13.1.4.3 Recent developments
 - 13.1.4.3.1 Deals
 - 13.1.4.4 MnM view
 - 13.1.4.4.1 Key strengths
 - 13.1.4.4.2 Strategic choices
 - 13.1.4.4.3 Weaknesses & competitive threats
- 13.1.5 QUVA PHARMA, INC.
 - 13.1.5.1 Business overview
 - 13.1.5.2 Products offered
 - 13.1.5.3 MnM view
 - 13.1.5.3.1 Key strengths
 - 13.1.5.3.2 Strategic choices
 - 13.1.5.3.3 Weaknesses & competitive threats
- 13.1.6 SCA PHARMA

- 13.1.6.1 Business overview
- 13.1.6.2 Products offered
- 13.1.6.3 Recent developments
 - 13.1.6.3.1 Deals
- 13.1.7 NEPHRON PHARMACEUTICALS
 - 13.1.7.1 Business overview
 - 13.1.7.2 Products offered
 - 13.1.7.3 Recent developments
 - 13.1.7.3.1 Expansions
- 13.1.8 LEITERS HEALTH
 - 13.1.8.1 Business overview
 - 13.1.8.2 Products offered
 - 13.1.8.3 Recent developments
 - 13.1.8.3.1 Expansions
- 13.1.9 ICON GROUP
 - 13.1.9.1 Business overview
 - 13.1.9.2 Products offered
 - 13.1.9.3 Recent developments
 - 13.1.9.3.1 Deals
- 13.1.10 ROSEWAY LABS
 - 13.1.10.1 Business overview
 - 13.1.10.2 Products offered
 - 13.1.10.3 Recent developments
 - 13.1.10.3.1 Other developments
- 13.1.11 ITH PHARMA
 - 13.1.11.1 Business overview
 - 13.1.11.2 Products offered
- 13.1.12 PENCOL COMPOUNDING PHARMACY
 - 13.1.12.1 Business overview
 - 13.1.12.2 Products offered
- 13.1.13 FORMUL8
 - 13.1.13.1 Business overview
 - 13.1.13.2 Products offered
- 13.1.14 AURORA COMPOUNDING PHARMACY
 - 13.1.14.1 Business overview
 - 13.1.14.2 Products offered
- 13.2 OTHER PLAYERS
 - 13.2.1 CUSTOM MED APOTHECARY
 - 13.2.2 INSTITUTIONAL PHARMACY SOLUTIONS

- 13.2.3 FUSION APOTHECARY
- 13.2.4 INNOVATION COMPOUNDING PHARMACY
- 13.2.5 RX3 COMPOUNDING PHARMACY
- 13.2.6 DOUGHERTY'S PHARMACY, INC.
- 13.2.7 LORRAINE'S PHARMACY
- 13.2.8 WELLS PHARMA
- 13.2.9 OLYMPIA PHARMACY
- 13.2.10 FRESH THERAPEUTICS
- 13.2.11 MEDIOS AG

14 APPENDIX

- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 COMPOUNDING PHARMACY MARKET: INCLUSIONS & EXCLUSIONS

TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS

TABLE 3 COMPOUNDING PHARMACY MARKET: RISK ANALYSIS

TABLE 4 COMPOUNDING PHARMACY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS

TABLE 5 COMPOUNDING PHARMACY MARKET: PORTER'S FIVE FORCES

TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPOUNDING PHARMACY PRODUCTS (%)

TABLE 7 KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER

TABLE 8 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (% OF GDP)

TABLE 9 US: CANCER INCIDENCE, BY STATE (2024)

TABLE 10 COMPOUNDING PHARMACY MARKET: ROLE IN ECOSYSTEM

TABLE 11 INDICATIVE PRICING ANALYSIS COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024

TABLE 12 INDICATIVE PRICING ANALYSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024

TABLE 13 COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026

TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 18 COUNTRY-WISE REGULATORY SCENARIO FOR COMPOUNDING PHARMACIES

TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 20 COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 21 COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 22 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 23 EUROPE: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 24 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 25 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 27 COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 28 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 29 EUROPE: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 30 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 31 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 33 COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 34 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 35 EUROPE: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 36 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 37 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 39 COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 40 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 41 EUROPE: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 42 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR

OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 43 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR
OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR
OPHTHALMIC DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 45 COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY
REGION, 2023–2030 (USD MILLION)

TABLE 46 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL
DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 47 EUROPE: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS,
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 48 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NASAL
DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 49 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL
DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR
NASAL DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 51 COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY
REGION, 2023–2030 (USD MILLION)

TABLE 52 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL
DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 53 EUROPE: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS,
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 54 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR RECTAL
DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 55 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL
DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR
RECTAL DRUGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 57 COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY
REGION, 2023–2030 (USD MILLION)

TABLE 58 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER
PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 59 EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER
PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 60 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER
PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 61 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER
PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 63 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 64 COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 65 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 66 EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 67 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 68 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 70 COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 71 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 72 EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 73 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 74 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 75 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 76 COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE

PHARMACEUTICAL MANUFACTURING, BY REGION, 2023–2030 (USD MILLION)

TABLE 77 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 78 EUROPE: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 79 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 80 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 81 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023–2030 (USD MILLION)

TABLE 82 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 83 COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)

TABLE 84 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 85 EUROPE: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 86 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 87 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 88 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)

TABLE 89 COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 90 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 91 EUROPE: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 92 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 93 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR

HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 94 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 95 COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 96 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 97 EUROPE: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 98 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 99 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 100 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 101 COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 102 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 103 EUROPE: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 104 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 105 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 106 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 107 COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 108 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 109 EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 110 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 111 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 112 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 113 COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 114 STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 115 NORTH AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 116 EUROPE: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 117 ASIA PACIFIC: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 118 LATIN AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 119 MIDDLE EAST & AFRICA: STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 120 NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 121 NORTH AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 122 EUROPE: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 123 ASIA PACIFIC: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 124 LATIN AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 125 MIDDLE EAST & AFRICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 126 COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 127 COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 128 NORTH AMERICA: COMPOUNDING PHARMACY MARKET ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 129 EUROPE: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 130 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 131 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 132 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR

ADULTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 133 COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 134 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 135 EUROPE: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 136 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 137 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 138 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 139 COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 140 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 141 EUROPE: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 142 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 143 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 144 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 145 COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 146 NORTH AMERICA: KEY MACROINDICATORS

TABLE 147 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 148 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 149 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 150 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 151 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 152 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY END

USER, 2023–2030 (USD MILLION)

TABLE 153 US: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 154 US: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 155 US: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 156 US: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 157 US: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 158 CANADA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 159 CANADA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 160 CANADA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 161 CANADA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 162 CANADA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 163 EUROPE: KEY MACROINDICATORS

TABLE 164 EUROPE: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 165 EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 166 EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 167 EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 168 EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 169 EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 170 GERMANY: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 171 GERMANY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 172 GERMANY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC

APPLICATION, 2023–2030 (USD MILLION)

TABLE 173 GERMANY: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 174 GERMANY: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 175 UK: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 176 UK: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 177 UK: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 178 UK: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 179 UK: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 180 FRANCE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 181 FRANCE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 182 FRANCE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 183 FRANCE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 184 FRANCE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 185 ITALY: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 186 ITALY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 187 ITALY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 188 ITALY: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 189 ITALY: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 190 SPAIN: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 191 SPAIN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 192 SPAIN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 193 SPAIN: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 194 SPAIN: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 195 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 196 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 197 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 198 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 199 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 200 ASIA PACIFIC: KEY MACROINDICATORS

TABLE 201 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 202 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 203 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 204 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 205 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 206 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 207 CHINA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 208 CHINA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 209 CHINA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 210 CHINA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 211 CHINA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 212 JAPAN: COMPOUNDING PHARMACY MARKET, BY PRODUCT,
2023–2030 (USD MILLION)

TABLE 213 JAPAN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING
TYPE, 2023–2030 (USD MILLION)

TABLE 214 JAPAN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC
APPLICATION, 2023–2030 (USD MILLION)

TABLE 215 JAPAN: COMPOUNDING PHARMACY MARKET, BY STERILITY,
2023–2030 (USD MILLION)

TABLE 216 JAPAN: COMPOUNDING PHARMACY MARKET, BY END USER,
2023–2030 (USD MILLION)

TABLE 217 INDIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,
2023–2030 (USD MILLION)

TABLE 218 INDIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING
TYPE, 2023–2030 (USD MILLION)

TABLE 219 INDIA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC
APPLICATION, 2023–2030 (USD MILLION)

TABLE 220 INDIA: COMPOUNDING PHARMACY MARKET, BY STERILITY,
2023–2030 (USD MILLION)

TABLE 221 INDIA: COMPOUNDING PHARMACY MARKET, BY END USER,
2023–2030 (USD MILLION)

TABLE 222 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,
2023–2030 (USD MILLION)

TABLE 223 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY
COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 224 AUSTRALIA : COMPOUNDING PHARMACY MARKET, BY
THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 225 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY STERILITY,
2023–2030 (USD MILLION)

TABLE 226 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY END USER,
2023–2030 (USD MILLION)

TABLE 227 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,
2023–2030 (USD MILLION)

TABLE 228 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY
COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 229 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY
THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 230 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY STERILITY,
2023–2030 (USD MILLION)

TABLE 231 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)

TABLE 232 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 233 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 234 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 235 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 236 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 237 LATIN AMERICA: KEY MACROINDICATORS

TABLE 238 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 239 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 240 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 241 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 242 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 243 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 244 BRAZIL: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 245 BRAZIL: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 246 BRAZIL: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 247 BRAZIL: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 248 BRAZIL: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 249 MEXICO: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 250 MEXICO: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 251 MEXICO: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC

APPLICATION, 2023–2030 (USD MILLION)

TABLE 252 MEXICO: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 253 MEXICO: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 254 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 255 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 256 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 257 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 258 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 259 MIDDLE EAST & AFRICA: KEY MACROINDICATORS

TABLE 260 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 261 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 262 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 263 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 264 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 265 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 266 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 267 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 268 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 269 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 270 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 271 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY

MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 272 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY
MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)

TABLE 273 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY
MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)

TABLE 274 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY
MARKET, BY STERILITY, 2023–2030 (USD MILLION)

TABLE 275 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY
MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 276 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN
COMPOUNDING PHARMACY MARKET, 2023–2025

TABLE 277 COMPOUNDING PHARMACY MARKET: DEGREE OF COMPETITION

TABLE 278 COMPOUNDING PHARMACY MARKET: REGION FOOTPRINT

TABLE 279 COMPOUNDING PHARMACY MARKET: PRODUCT FOOTPRINT

TABLE 280 COMPOUNDING PHARMACY MARKET: THERAPEUTIC APPLICATION
FOOTPRINT

TABLE 281 COMPOUNDING PHARMACY MARKET: STERILITY FOOTPRINT

TABLE 282 COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY
STARTUP/SME PLAYERS

TABLE 283 COMPOUNDING PHARMACY MARKET: COMPETITIVE
BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT,
THERAPEUTIC APPLICATION, AND REGION, 2024

TABLE 284 COMPOUNDING PHARMACY MARKET: PRODUCT LAUNCHES,
JANUARY 2022–OCTOBER 2025

TABLE 285 COMPOUNDING PHARMACY MARKET: DEALS, JANUARY
2022–OCTOBER 2025

TABLE 286 COMPOUNDING PHARMACY MARKET: EXPANSIONS, JANUARY
2022–OCTOBER 2025

TABLE 287 BAXTER: COMPANY OVERVIEW

TABLE 288 BAXTER: PRODUCTS OFFERED

TABLE 289 BAXTER: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025

TABLE 290 EMPOWER PHARMACY: COMPANY OVERVIEW

TABLE 291 EMPOWER PHARMACY: PRODUCTS OFFERED

TABLE 292 EMPOWER PHARMACY: EXPANSIONS, JANUARY 2022–OCTOBER
2025

TABLE 293 B. BRAUN SE: COMPANY OVERVIEW

TABLE 294 B. BRAUN SE: PRODUCTS OFFERED

TABLE 295 B. BRAUN SE: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025

TABLE 296 FAGRON: COMPANY OVERVIEW

TABLE 297 FAGRON: PRODUCTS OFFERED
TABLE 298 FAGRON: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 299 QUVA PHARMA, INC.: COMPANY OVERVIEW
TABLE 300 QUVA PHARMA, INC.: PRODUCTS OFFERED
TABLE 301 SCA PHARMA: COMPANY OVERVIEW
TABLE 302 SCA PHARMA: PRODUCTS OFFERED
TABLE 303 SCA PHARMA: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 304 NEPHRON PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 305 NEPHRON PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 306 NEPHRON PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 307 LEITERS HEALTH: COMPANY OVERVIEW
TABLE 308 LEITERS HEALTH: PRODUCTS OFFERED
TABLE 309 LEITERS HEALTH: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 310 ICON GROUP: COMPANY OVERVIEW
TABLE 311 ICON GROUP: PRODUCTS OFFERED
TABLE 312 ICON GROUP: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 313 ROSEWAY LABS: COMPANY OVERVIEW
TABLE 314 ROSEWAY LABS: PRODUCTS OFFERED
TABLE 315 ROSEWAY LABS: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025
TABLE 316 ITH PHARMA: COMPANY OVERVIEW
TABLE 317 ITH PHARMA: PRODUCTS OFFERED
TABLE 318 PENCOL COMPOUNDING PHARMACY: COMPANY OVERVIEW
TABLE 319 PENCOL COMPOUNDING PHARMACY: PRODUCTS OFFERED
TABLE 320 FORMUL8: COMPANY OVERVIEW
TABLE 321 FORMUL8: PRODUCTS OFFERED
TABLE 322 AURORA COMPOUNDING PHARMACY: COMPANY OVERVIEW
TABLE 323 AURORA COMPOUNDING PHARMACY: PRODUCTS OFFERED
TABLE 324 CUSTOM MED APOTHECARY: COMPANY OVERVIEW
TABLE 325 INSTITUTIONAL PHARMACY SOLUTIONS: COMPANY OVERVIEW
TABLE 326 FUSION APOTHECARY: COMPANY OVERVIEW
TABLE 327 INNOVATION COMPOUNDING PHARMACY: COMPANY OVERVIEW
TABLE 328 RX3 COMPOUNDING PHARMACY: COMPANY OVERVIEW
TABLE 329 DOUGHERTY'S PHARMACY, INC.: COMPANY OVERVIEW
TABLE 330 LORRAINE'S PHARMACY: COMPANY OVERVIEW
TABLE 331 WELLS PHARMA: COMPANY OVERVIEW
TABLE 332 OLYMPIA PHARMACY: COMPANY OVERVIEW
TABLE 333 FRESH THERAPEUTICS: COMPANY OVERVIEW

TABLE 334 MEDIOS AG: COMPANY OVERVIEW

List Of Figures

LIST OF FIGURES

FIGURE 1 COMPOUNDING PHARMACY MARKET SEGMENTATION & REGIONAL SCOPE

FIGURE 2 COMPOUNDING PHARMACY MARKET: YEARS CONSIDERED

FIGURE 3 COMPOUNDING PHARMACY MARKET: RESEARCH DESIGN

FIGURE 4 COMPOUNDING PHARMACY MARKET: KEY DATA FROM SECONDARY SOURCES

FIGURE 5 COMPOUNDING PHARMACY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS

FIGURE 6 COMPOUNDING PHARMACY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024

FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)

FIGURE 8 REVENUE SHARE ANALYSIS OF BAXTER (2024)

FIGURE 9 COMPOUNDING PHARMACY MARKET SIZE VALIDATION FROM PRIMARY SOURCES

FIGURE 10 COMPOUNDING PHARMACY MARKET: TOP-DOWN APPROACH

FIGURE 11 COMPOUNDING PHARMACY MARKET: CAGR PROJECTIONS

FIGURE 12 COMPOUNDING PHARMACY MARKET: DATA TRIANGULATION

FIGURE 13 COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)

FIGURE 14 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 15 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD MILLION)

FIGURE 16 COMPOUNDING PHARMACY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 17 REGIONAL SNAPSHOT OF COMPOUNDING PHARMACY MARKET

FIGURE 18 RISING TREND OF PERSONALISED MEDICINES TO PROPEL MARKET GROWTH

FIGURE 19 US AND ORAL DRUGS SEGMENT TO COMMAND LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025

FIGURE 20 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD

FIGURE 22 COMPOUNDING PHARMACY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 23 TOTAL PRESCRIPTION DRUG SALES, 2023–2030 (USD BILLION)

FIGURE 24 COMPOUNDING PHARMACY MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF KEY COMPOUNDING PHARMACY PRODUCTS

FIGURE 26 KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER

FIGURE 27 GLOBAL PHARMACEUTICAL R&D EXPENDITURE, 2023–2030 (USD BILLION)

FIGURE 28 COMPOUNDING PHARMACY MARKET: VALUE CHAIN ANALYSIS

FIGURE 29 COMPOUNDING PHARMACY MARKET: ECOSYSTEM MAP

FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES IN COMPOUNDING PHARMACY MARKET

FIGURE 31 INVESTMENT AND NUMBER OF DEALS IN COMPOUNDING PHARMACY MARKET, 2023–2025 (USD MILLION)

FIGURE 32 COMPOUNDING PHARMACY MARKET: IMPACT OF AI/GEN AI

FIGURE 33 NORTH AMERICA: COMPOUNDING PHARMACY MARKET SNAPSHOT

FIGURE 34 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET SNAPSHOT

FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2022–2024 (USD MILLION)

FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET (2024)

FIGURE 37 COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 38 COMPOUNDING PHARMACY MARKET: COMPANY FOOTPRINT

FIGURE 39 COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 40 EV/EBITDA OF KEY VENDORS

FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 42 COMPOUNDING PHARMACY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS

FIGURE 43 BAXTER: COMPANY SNAPSHOT (2024)

FIGURE 44 B. BRAUN SE: COMPANY SNAPSHOT (2024)

FIGURE 45 FAGRON: COMPANY SNAPSHOT (2024)

I would like to order

Product name: Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), End User (Pediatric, Adult) - Global forecast to 2030

Product link: <https://marketpublishers.com/r/C745F3E6C527EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C745F3E6C527EN.html>